Search Results

Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs.

• Authors : Naci H; Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.; Guan X

Subjects: Data Display* ; Drug Labeling*/Drug Labeling*/Drug Labeling*/methods ; Drug Labeling*/Drug Labeling*/Drug Labeling*/standards

• Source: JAMA internal medicine [JAMA Intern Med] 2021 Nov 01; Vol. 181 (11), pp. 1521-1522.Publisher: American Medical Association Country of Publication: United States NLM ID: 101589534 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.

• Authors : Shea MB; 1 Friends of Cancer Research, Washington, DC, USA.; Stewart M

Subjects: Antineoplastic Agents*; Drug Labeling/Drug Labeling/Drug Labeling/*standards ; Off-Label Use/Off-Label Use/Off-Label Use/*statistics & numerical data

• Source: Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2018 Nov; Vol. 52 (6), pp. 771-777. Date of Electronic Publication: 2018 Mar 05.Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101597411 Publication Model: Print-Electronic Cited Medium:

Record details

Lurbinectedin.

Subjects: Drug Labeling*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Carbolines/Carbolines/Carbolines/*pharmacology

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2020 Oct 30; Vol. 77 (22), pp. Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Decitabine and Cedazuridine.

Subjects: Drug Labeling*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Decitabine/Decitabine/Decitabine/*pharmacology

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2020 Oct 30; Vol. 77 (22), pp. Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium: Internet ISSN:

Record details

U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.

• Authors : Pulte ED; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA .; Wroblewski T

Subjects: Drug Labeling*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*administration & dosage ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/Leukemia, Myelogenous, Chronic, BCR-ABL Positive/Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy

• Source: The oncologist [Oncologist] 2019 May; Vol. 24 (5), pp. e188-e195. Date of Electronic Publication: 2019 Apr 24.Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).

• Authors : Gnanasakthy A; RTI Health Solutions, Research Triangle Park, NC, USA. Electronic address: .; Barrett A

Subjects: Drug Approval* ; Patient Reported Outcome Measures*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*standards

• Source: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2019 Feb; Vol. 22 (2), pp. 203-209.Publisher: Elsevier Country of Publication: United States NLM ID: 100883818 Publication Model: Print Cited Medium: Internet ISSN: 1524-4733

Record details

Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.

• Authors : Shepshelovich D; Daniel Shepshelovich, Hadar Goldvaser, and Eitan Amir, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Daniel Shepshelovich and Hadar Goldvaser, Tel-Aviv University, Tel Aviv, Israel

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*administration & dosage ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*adverse effects ; Drug Approval/Drug Approval/Drug Approval/*methods

• Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Jun 20; Vol. 36 (18), pp. 1798-1804. Date of Electronic Publication: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium:

Record details

Labeling Changes for Vinca Alkaloid Chemotherapies.

• Authors : Aschenbrenner DS; Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch : .

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*administration & dosage ; Drug Labeling/Drug Labeling/Drug Labeling/*standards ; Vinca Alkaloids/Vinca Alkaloids/Vinca Alkaloids/*administration & dosage

• Source: The American journal of nursing [Am J Nurs] 2021 May 01; Vol. 121 (5), pp. 25.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372646 Publication Model: Print Cited Medium: Internet ISSN:

Record details

FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.

• Authors : Kluetz PG; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland. .; Keegan P

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Drug Labeling/Drug Labeling/Drug Labeling/*legislation & jurisprudence ; Neoplasms/Neoplasms/Neoplasms/*drug therapy

• Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Feb 15; Vol. 27 (4), pp. 916-921. Date of Electronic Publication: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies.

• Authors : Gafter-Gvili A; Department of Medicine A, Rabin Medical Center, Petah Tikva, Israel.; Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*adverse effects ; Drug Labeling/Drug Labeling/Drug Labeling/*legislation & jurisprudence ; Hematologic Neoplasms/Hematologic Neoplasms/Hematologic Neoplasms/*pathology

• Source: Acta haematologica [Acta Haematol] 2020; Vol. 143 (1), pp. 73-77. Date of Electronic Publication: 2019 Jun 05.Publisher: Karger Country of Publication: Switzerland NLM ID: 0141053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9662

Record details